Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
Flora HuangChristine Brezden-MasleyKelvin K W ChanJoseph J BarfettAnish KirpalaniDjeven P DevaLaura Jimenez-JuanAshita BarthurLan SongBinita ChackoMing-Yen NgKim ConnellyKathy C K WongAndrew T YanPublished in: European radiology (2022)
• In trastuzumab-treated breast cancer patients evaluated by cardiac MRI, left atrial ejection fraction declined and minimum volume increased during treatment and recovered to baseline after trastuzumab cessation. • Changes in left atrial ejection fraction correlated with changes in left ventricular ejection fraction in the first 6 months of trastuzumab treatment. • Trastuzumab therapy is associated with concurrent detrimental effects on left atrial and ventricular remodeling.
Keyphrases
- left atrial
- ejection fraction
- left ventricular
- aortic stenosis
- epidermal growth factor receptor
- mitral valve
- metastatic breast cancer
- atrial fibrillation
- catheter ablation
- hypertrophic cardiomyopathy
- heart failure
- acute myocardial infarction
- cardiac resynchronization therapy
- tyrosine kinase
- magnetic resonance imaging
- early stage
- stem cells
- contrast enhanced
- squamous cell carcinoma
- bone marrow
- young adults
- transcatheter aortic valve replacement
- replacement therapy